EUVIMEDObjevte EUVIMED
Fallbericht

Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report

Şeyma Handan AKYÖN, Yeşer GENÇ

Turkish Journal of Internal Medicine · 2022

DOI: 10.46310/tjim.1072232 ↗

At a glance

Fallbericht in Turkish Journal of Internal Medicine, 2022. Written by Şeyma Handan AKYÖN and 1 co-authors. 17 references.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

After the pandemic started, vaccines against SARS-CoV-2 were developed and applied in a short time. Later, various side effects were reported during the use of these vaccines. Among the skin side effects, besides local skin reactions at the injection site, urticaria, maculopapular rash and pityriasis rosea-like reactions were observed. We presented a female case who developed pityriasis rosea after administering the 3rd dose of the Pfizer-BioNTech COVID-19 vaccine.

Cite

APA

AKYÖN, Ş. H., & GENÇ, Y. (2022). Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1072232

Vancouver

AKYÖN ŞH, GENÇ Y. Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1072232

BibTeX
@article{AKYN2022,
  author = {AKYÖN, Şeyma Handan and GENÇ, Yeşer},
  title = {Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report},
  journal = {Turkish Journal of Internal Medicine},
  year = {2022},
  doi = {10.46310/tjim.1072232}
}
Start for free →